# Shionogi

Source: https://onco.cc/companies/shionogi/  
OnCo record `shionogi` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shionogi is a long-established Osaka pharmaceutical company, best known for antibiotics and antivirals, that developed the platinum chemotherapy nedaplatin sold in Japan as Aqupla.

## Summary

Shionogi, founded in Osaka in 1878, is a research-based pharmaceutical company with strengths in infectious disease, including the antiviral Xofluza and the antibiotic cefiderocol, and in pain and central nervous system medicines. In oncology it developed nedaplatin (254-S), a second-generation platinum agent with less kidney toxicity than cisplatin, approved in Japan in 1995 as Aqupla for head and neck, lung, oesophageal, bladder, cervical, ovarian and testicular cancers.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Shionogi & Co., Ltd.; 塩野義製薬; TSE:4507
- Tags: drug-maker
- HQ: Osaka
- Type: pharma
- Website: https://www.shionogi.com/
- Ticker: TSE:4507

## Sources

- Official website: https://www.shionogi.com/

## Connected records

- drugs: [Nedaplatin](https://onco.cc/drugs/nedaplatin/)

---
JSON: https://onco.cc/api/v1/entities/shionogi.json